Shots:

• The safety of BYFAVO was evaluated in 969 patients assessing Byfavo for the induction and maintenance of procedural sedation
• In Jan 2020- the company in-licensed the commercial rights to Byfavo and will pay €30M upfront generated by the approval- consisting of €15M in cash and €15M in ordinary shares of Acacia Pharma stock. Additionally- Acacia will get €10M net cash to launch the product in the US
• Byfavo (remimazolam) is an injection rapid onset/offset IV benzodiazepine sedative for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less- with its expected launch in the US in H2’20

­ Ref: Acacia Pharma | Image: Acacia Pharma